CRIS Current Research Information System

ALTAVILLA, AMELIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.862
NA - Nord America 720
EU - Europa 353
SA - Sud America 136
AF - Africa 58
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.135
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 703
SG - Singapore 536
VN - Vietnam 463
CN - Cina 450
HK - Hong Kong 186
BR - Brasile 106
KR - Corea 91
IT - Italia 77
DE - Germania 62
FR - Francia 48
NL - Olanda 39
FI - Finlandia 33
IN - India 32
JP - Giappone 27
SC - Seychelles 23
GB - Regno Unito 21
SE - Svezia 21
AR - Argentina 13
PH - Filippine 11
IQ - Iraq 10
AT - Austria 9
BD - Bangladesh 9
IE - Irlanda 8
MX - Messico 8
CI - Costa d'Avorio 7
ID - Indonesia 7
TH - Thailandia 7
CO - Colombia 6
ES - Italia 6
PL - Polonia 6
RU - Federazione Russa 6
TR - Turchia 6
AU - Australia 5
SA - Arabia Saudita 5
TW - Taiwan 5
ZA - Sudafrica 5
CA - Canada 4
KE - Kenya 4
PK - Pakistan 4
CL - Cile 3
EC - Ecuador 3
MA - Marocco 3
UZ - Uzbekistan 3
AL - Albania 2
BE - Belgio 2
BG - Bulgaria 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
EG - Egitto 2
ET - Etiopia 2
GR - Grecia 2
HN - Honduras 2
JO - Giordania 2
MD - Moldavia 2
MU - Mauritius 2
MY - Malesia 2
PY - Paraguay 2
TG - Togo 2
TN - Tunisia 2
UA - Ucraina 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GH - Ghana 1
GT - Guatemala 1
KG - Kirghizistan 1
LT - Lituania 1
LY - Libia 1
MN - Mongolia 1
NG - Nigeria 1
NP - Nepal 1
OM - Oman 1
SN - Senegal 1
SY - Repubblica araba siriana 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.135
Salva come PNG Salva come JPEG
Città #
Singapore 366
Hefei 200
Hong Kong 165
San Jose 164
Ho Chi Minh City 130
Hanoi 128
Santa Clara 113
Ashburn 99
Seoul 85
Beijing 56
Los Angeles 55
Boardman 45
Da Nang 32
Chandler 27
Helsinki 27
Tokyo 26
Buffalo 24
Lauterbourg 24
Bengaluru 18
Bologna 17
Haiphong 17
Munich 16
Council Bluffs 14
Rome 14
Falkenstein 11
Frankfurt am Main 11
Nuremberg 10
New York 9
Shenzhen 9
Dublin 8
Abidjan 7
Guangzhou 7
Shanghai 7
Baghdad 6
London 6
Rio de Janeiro 6
Thái Nguyên 6
Tongling 6
Chicago 5
Düsseldorf 5
Nha Trang 5
Redondo Beach 5
Turin 5
Warsaw 5
Bexley 4
Biên Hòa 4
Bắc Ninh 4
Bến Tre 4
Changsha 4
Dallas 4
Johannesburg 4
Lappeenranta 4
Nairobi 4
Princeton 4
Salt Lake City 4
Santo André 4
Stockholm 4
Wuhan 4
Bangkok 3
Bắc Giang 3
Curitiba 3
Harbin 3
Huế 3
Jakarta 3
Lang Son 3
Marseille 3
Melbourne 3
Milan 3
Ninh Bình 3
Recife 3
São Paulo 3
Tampa 3
Vienna 3
Việt Trì 3
Vũng Tàu 3
Addis Ababa 2
Ankara 2
Ann Arbor 2
Athens 2
Baoding 2
Bari 2
Berlin 2
Bern 2
Bogotá 2
Bolzano 2
Brooklyn 2
Brussels 2
Busto Arsizio 2
Bảo Lộc 2
Cao Lanh 2
Caxias do Sul 2
Charlotte 2
Denver 2
Des Moines 2
Dongguan 2
Florence 2
Florianópolis 2
Fort Worth 2
Fortaleza 2
Genoa 2
Totale 2.158
Salva come PNG Salva come JPEG
Nome #
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer 204
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 188
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 178
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 146
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 144
PATIENT'S ATTITUDES TOWARDS TREATMENT IN ADVANCED CANCER: HOW THESE ARE IDENTIFIED FROM THEIR PHYSICIAN? 107
ANTIANGIOGENIC AGENTS ARE INEFFECTIVE TO INCREASE COMPLETE RESPONSE RATE IN MRCC. A META-ANALYSIS 99
CAR-T cell therapy: A potential new strategy against prostate cancer 99
Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA) 98
Caregiver emotional burden in testicular cancer patients: From patient to caregiver support 94
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide 91
RELATIONSHIP BETWEEN ENZALUTAMIDE ACTIVITY AND PREVIOUS ANTIANDROGEN WITHDRAWAL SYNDROME (AWS) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) 89
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 87
BENEFIT OF POST-DOCETAXEL TREATMENT IN CASTRATION RESISTANT PROSTATE CANCER PATIENTS WITH POOR PERFORMANCE STATUS 84
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: A position paper of the MeetURO Group 83
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses 83
KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 83
Predicting positive bone marrow biopsies (BMBs) in patients (PTS) with advanced prostate cancer (APC) 81
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide 73
Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management 73
Corrigendum to Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis [Ann Oncol 26, 2015 2107-2113] (doi: 10.1093/annonc/mdv315)] 67
ERLOTINIB RELATED TOXICITY IN ELDERLY PATIENTS AFFECTED BY NON-SMALL CELL LUNG CANCER (NSCLC) 65
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate 63
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 62
Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study 60
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents 58
Visceral disease in castration-resistant prostate cancer 58
Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis 56
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone 55
Dynamic Contrast-enhanced Magnetic Resonance Imaging in the Early Evaluation of Anti-angiogenic Therapy in Metastatic Renal Cell Carcinoma 51
Correlation of [68Ga]Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study 50
Immune system and DNA repair defects in ovarian cancer: Implications for locoregional approaches 46
Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies 45
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: Any place in the modern treatment scenario? An intention to treat evaluation 44
Clinical and pathological features of primary renal synovial sarcoma: Analysis of 64 cases from 11 years of medical literature 25
Clinical and pathological features of primary neuroectodermal tumor/ewing sarcoma of the kidney 25
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone 24
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant 24
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant 24
Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy 22
Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules 20
Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: A personal view 19
Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma 19
Post-docetaxel therapy in castration resistant prostate cancer – the forest is growing in the desert 18
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials 18
null 2
Totale 3.204
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.686
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.686
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202239 0 0 0 0 0 0 6 1 1 10 12 9
2022/202362 4 10 2 10 7 9 0 1 11 0 3 5
2023/202440 2 3 1 0 1 6 0 15 5 1 2 4
2024/2025875 55 84 41 46 175 54 34 27 7 67 46 239
2025/20262.188 191 302 180 206 212 49 415 149 393 91 0 0
Totale 3.204